'On standalone basis
Quarter ended December 2025 compared with Quarter ended December 2024.
Net sales (including other operating income) of RPG Life Sciences has increased 4.24% to Rs 180.03 crore. Operating profit margin has declined from 28.46% to 22.09%, leading to 19.12% decline in operating profit to Rs 39.76 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 17.81% to 17.97%. Purchase of finished goods cost rose from 13.39% to 22.54%. Employee cost increased from 16.94% to 18.25%. Other expenses fell from 22.85% to 20.69%.
Other income up 3.02% to Rs 3.41 crore. PBIDT fell 17.72% to Rs 43.17 crore. Provision for interest up 108.33% to Rs 0.25 crore.
PBDT fell 18.01% to Rs 42.92 crore. Provision for depreciation down 1.47% to Rs 5.38 crore.
Profit before tax down 19.94% to ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|